A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia.

Trial Profile

A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2013

At a glance

  • Drugs KAI 1678 (Primary) ; Lidocaine
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors KAI Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2010 New source identified and integrated ( ClinicalTrials.gov: US National Institutes of Health NCT01106716)
    • 21 Apr 2010 Planned patient number (24) added as reported by ClinicalTrials.gov.
    • 21 Apr 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top